Preclinical pharmacology and phase I clinical trialsBURRIS, H. A.The Annals of pharmacotherapy. 1994, Vol 28, Num 5, pp S7-S10, issn 1060-0280, SUPArticle

The evolving role of oral topotecanBURRIS, H. A.Seminars in hematology. 1999, Vol 36, Num 4, pp 26-32, issn 0037-1963, SUP8Article

Vinorelbine : A new antineoplastic drug for the treatment of non-small-cell lung cancerFIELDS JONES, S; BURRIS, H. A.The Annals of pharmacotherapy. 1996, Vol 30, Num 5, pp 501-506, issn 1060-0280Article

Testicular relapse in adult acute myelogenous leukemiaSHAFFER, D. W; BURRIS, H. A; O'ROURKE, T et al.Cancer. 1992, Vol 70, Num 6, pp 1541-1544, issn 0008-543XArticle

Docetaxel (taxotere) in HER-2-positive patients and in combination with trastuzumab (herceptin)BURRIS, H. A.Seminars in oncology. 2000, Vol 27, Num 2, pp 19-23, issn 0093-7754, SUP3Article

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needsBURRIS, H. A.Oncogene (Basingstoke). 2009, Vol 28, issn 0950-9232, S4-S13, SUP1Article

Single-agent docetaxel (Taxotere) in randomized phase III trialsBURRIS, H. A.Seminars in oncology. 1999, Vol 26, Num 3, pp 1-6, issn 0093-7754, SUP9Article

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2PICCART, M; HORTOBAGYI, G. N; BURRIS, H. A et al.Annals of oncology. 2014, Vol 25, Num 12, pp 2357-2362, issn 0923-7534, 6 p.Article

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsINFANTE, J. R; KURZROCK, R; HUSZAR, D et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 165-172, issn 0344-5704, 8 p.Article

Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancerBURRIS, H. A; HAINSWORTH, J. D; ERLAND, J. B et al.Seminars in oncology. 2000, Vol 27, Num 1, pp 9-13, issn 0093-7754, SUP2Article

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignanciesVILLALONA-CALERO, M. A; WEISS, G. R; GRIFFIN, T et al.Journal of clinical oncology. 1999, Vol 17, Num 6, pp 1915-1925, issn 0732-183XArticle

Phase II trial of docetaxel for cholangiocarcinomaPAZDUR, R; ROYCE, M. E; RODRIGUEZ, G. I et al.American journal of clinical oncology. 1999, Vol 22, Num 1, pp 78-81, issn 0277-3732Article

Docetaxel (Taxotere) in combination : A step forwardBURRIS, H. A; FIELDS, S; PEACOCK, N et al.Seminars in oncology. 1995, Vol 22, Num 6, pp 35-40, issn 0093-7754, SUP13Conference Paper

New anticancer agentsWEISS, G. R; BURRIS, H. A; ECKARDT, J. R et al.Cancer chemotherapy and biological response modifiers annual. 1994, Vol 15, pp 130-151, issn 0921-4410Article

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignanciesSHAFFER, D. W; SMITH, L. S; VON HOFF, D. D et al.Cancer research (Baltimore). 1993, Vol 53, Num 24, pp 5929-5933, issn 0008-5472Article

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancerCROWN, J; KENNEDY, M. J; DIÉRAS, V et al.Annals of oncology. 2013, Vol 24, Num 8, pp 2005-2011, issn 0923-7534, 7 p.Article

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A minnie pearl cancer research network Phase II trialHAINSWORTH, J. D; BURRIS, H. A; LITCHY, S et al.Cancer. 2000, Vol 89, Num 2, pp 328-333, issn 0008-543XArticle

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancerHAINSWORTH, J. D; BURRIS, H. A; MORRISSEY, L. H et al.Cancer. 1999, Vol 85, Num 5, pp 1179-1185, issn 0008-543XArticle

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in Patients with advanced cancerSCHILSKY, R. L; HOHNEKER, J; RATAIN, M. J et al.Journal of clinical oncology. 1998, Vol 16, Num 4, pp 1450-1457, issn 0732-183XArticle

Phase II trial of topotecan in advanced gastric cancer : A Southwest Oncology Group studyBENEDETTI, J. K; BURRIS, H. A; BALCERZAK, S. P et al.Investigational new drugs. 1997, Vol 15, Num 3, pp 261-264, issn 0167-6997Article

Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities : a report of three casesBATTAFARANO, D. F; ZIMMERMAN, G. C; OLDER, S. A et al.Cancer. 1995, Vol 76, Num 1, pp 110-115, issn 0008-543XArticle

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalationRINALDI, D. A; BURRIS, H. A; CLARK, G et al.Journal of clinical oncology. 1995, Vol 13, Num 11, pp 2842-2850, issn 0732-183XArticle

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancerRAVDIN, P. M; BURRIS, H. A; COOK, G et al.Journal of clinical oncology. 1995, Vol 13, Num 12, pp 2879-2885, issn 0732-183XArticle

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapyBEDIKIAN, A. Y; WEISS, G. R; BENJAMIN, R. S et al.Journal of clinical oncology. 1995, Vol 13, Num 12, pp 2895-2899, issn 0732-183XArticle

Phase I and pharmacokinetic trial of weekly CPT-11ROTHENBERG, M. L; KUHN, J. G; ROCK, M. K et al.Journal of clinical oncology. 1993, Vol 11, Num 11, pp 2194-2204, issn 0732-183XArticle